Ma Songjiang's Form 4 filing
Gyre Therapeutics, Inc. (GYRE) · filed Feb 11, 2025
- Accession no.
- 0001140361-25-003831
- Filed
- Feb 11, 2025
- Trade date
- Feb 6-7, 2025
- Filing delay
- 5 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $50.0K. It was filed 5 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ma SongjiangCIK 0001985547 | Director, Officer (President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.70 to $13.05. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.01 to $12.475. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.